INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 ... - Morningstar
INmune Bio Inc. announced exceptional performance of EMACC in AD02 Phase II Alzheimer's trial, showing significant correlation with CDR-SB. EMACC, designed for objective cognitive change measurement, demonstrated high precision and differentiation capability between disease stages.
Reference News
INmune Bio Announces Data From AD02 Phase II Alzheimer's Trial - RTTNews
INmune Bio's AD02 Phase II Alzheimer's trial shows exceptional EMACC performance, significant correlation with CDR-SB, and accurate disease stage differentiation. Stock up 2.32%.
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 ... - Morningstar
INmune Bio Inc. announced exceptional performance of EMACC in AD02 Phase II Alzheimer's trial, showing significant correlation with CDR-SB. EMACC, designed for objective cognitive change measurement, demonstrated high precision and differentiation capability between disease stages.